Myeloid derived suppressor cells (MDSCs) are defined in mice on the basis of CD11b and
Gr-1 marker expression and the functional ability to inhibit T lymphocyte activation. …

Emerging evidence indicates that the Achilles' heel of cancer immunotherapies is often the
complex interplay of tumor‐derived factors and deviant host properties, which involve a wide …

In tumor-bearing mice and cancer patients, tumor progression is often associated with
altered hematopoiesis leading to the accumulation of myeloid cells. Extensive studies in …

Active suppression of tumor-specific T lymphocytes can limit the efficacy of immune surveillance
and immunotherapy. While tumor-recruited CD11b + myeloid cells are known mediators …

Tumor growth is associated with a profound alteration in myelopoiesis, leading to recruitment
of immunosuppressive cells known as myeloid-derived suppressor cells (MDSCs). We …

Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) are agents
currently in clinical use for nonmalignant conditions. We report the use of PDE5 inhibitors as …

CD11b + /Gr‐1 + myeloid‐derived suppressor cells (MDSC) contribute to tumor immune
evasion by restraining the activity of CD8 + T‐cells. Two major MDSC subsets were recently …

The immunosuppressive activity of mesenchymal stromal cells (MSCs) is well documented.
However, the therapeutic benefit is completely unpredictable, thus raising concerns about …

Active suppression of tumor-specific T lymphocytes can limit the immune-mediated destruction
of cancer cells. Of the various strategies used by tumors to counteract immune attacks, …

A heterogeneous set of cells that are commonly grouped as “myeloid cells”, interacts in a
complex landscape of physiological and pathological situations. In this review we attempt to …